Last reviewed · How we verify

NCT06898788: PAD

Probiotic Administration for Adolescent Depression

Recruiting now EARLY_PHASE1 Last updated 4 June 2025
What this trial tests

EARLY_PHASE1 trial testing Visbiome in Depression in 77 participants. Currently enrolling.

Timeline
15 May 2025
Primary endpoint
1 August 2026
1 December 2026

Quick facts

Lead sponsorUniversity of California, San Francisco
PhaseEARLY_PHASE1
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposeother
Enrollment77
Start date15 May 2025
Primary completion1 August 2026
Estimated completion1 December 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of California, San Francisco

Who can join

Adults 15 to 24, any sex, with Depression. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

This double-blind, placebo-controlled clinical trial will examine the effect of probiotic Visbiome on the brain and gut microbiome of individuals 15 to 24 years of age.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Visbiome

Trials testing the same drug.

Other recruiting trials for Depression

Currently open trials in the same condition.

Other University of California, San Francisco trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06898788.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing